Q-omics provides the consensus-scored ORMDL3 profile across patient tissues and cancer cell-line models. ORMDL3 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ORMDL3 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ORMDL3 RNA expression shows 20,552 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, KICH, and ACC as cancer lineages where ORMDL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ORMDL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ORMDL3 survival associations across molecular data types. ORMDL3 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ORMDL3 RNA expression–survival associations across cancer types. High ORMDL3 expression shows unfavorable associations in HNSC and LGG, but favorable associations in LUAD, SCLC, BLCA and THCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ORMDL3 RNA expression.
This table summarizes ORMDL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ORMDL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ORMDL3 shows lower tumor expression in KICH, KIRC and CHOL and higher tumor expression in HNSC, COAD and STAD. The KICH box plot shows higher ORMDL3 RNA expression in normal versus tumor tissue (log2 FC = −1.445, t-test p < 0.001).
This table shows molecular features associated with ORMDL3 in patient tissues and cancer cell lines. In patient samples, ORMDL3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ORMDL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
